Cara Therapeutics (CARA) has provided an update.
Cara Therapeutics, Inc. recently announced that their oral medication difelikefalin did not show significant benefits in treating severe itching associated with notalgia paresthetica compared to a placebo. Consequently, the company has decided to halt the clinical trials for this program. This news is notable for investors as it may impact the company’s future prospects and stock performance.
For detailed information about CARA stock, go to TipRanks’ Stock Analysis page.
